Executive SummaryThe stock-market hysteria surrounding EntreMed is only the latest in a series of events we list in which an extraordinary quotation dramatically drives up the stock of a company almost overnight. The hype isn't all bad, it turns out.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.